A PHASE 3, MUTLICENTER, OPEN-LABEL EXTENSION STUDY OF PATIDEGIB TROPICAL GEL, 2 % IN SUBJECTS WITH GORLIN SYNDROME (BASAL CELL NEVUS SYNDROME)
- Registry ID
- PELLE-926-301E
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- PELLEPHARM, INC
- Last update
- 2020-08-26
Conditions
- BASAL CELL NEVUS SYNDROME
View on source registry